Cure My Disease

Don't miss your cure!

 Log in / Sign up

Breast cancer drug tested in everyday patients

NCT ID NCT05293470

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tracks the safety and effectiveness of Piqray (Alpelisib) in people with a specific type of advanced breast cancer (HR+, HER2-, with a PIK3CA mutation). It includes postmenopausal women and men whose cancer worsened after hormone therapy. Researchers observe patients in real-world settings to see how well the drug works and what side effects occur.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Alpelisib (Piqray)
What this could lead to
If successful, this study could confirm that Piqray works well and is safe in everyday clinical practice for people with a specific type of advanced breast cancer.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. Side effects like high blood sugar or rash are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

  • Novartis Investigative Site

    RECRUITING

    Cheonan Si, Chungcheongnam-do, 31116, South Korea

  • Novartis Investigative Site

    RECRUITING

    Daegu, Dalseo gu, 42602, South Korea

  • Novartis Investigative Site

    RECRUITING

    Goyang-si, Gyeonggi-do, 10475, South Korea

  • Novartis Investigative Site

    RECRUITING

    Suwon, Gyeonggi-do, 16499, South Korea

  • Novartis Investigative Site

    RECRUITING

    Gyeonggi-do, Korea, 11765, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, Korea, 02841, South Korea

  • Novartis Investigative Site

    COMPLETED

    Seoul, Seoul, 06351, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, Seoul, 150-713, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, Yangcheon gu, 07985, South Korea

  • Novartis Investigative Site

    RECRUITING

    Busan, 48108, South Korea

  • Novartis Investigative Site

    RECRUITING

    Busan, 602-030, South Korea

  • Novartis Investigative Site

    RECRUITING

    Daegu, 705 718, South Korea

  • Novartis Investigative Site

    RECRUITING

    Daejeon, 302-241, South Korea

  • Novartis Investigative Site

    RECRUITING

    Jeollanam, 519763, South Korea

  • Novartis Investigative Site

    RECRUITING

    Kyunggi, 425-020, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, 03722, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, 04763, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, 05505, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, 06273, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.